Aim: Perform treatment planning adaptations for proton therapy to correct for hypoxia in head and neck cancer (HNC). Material and methods: Hypoxic subvolumes were defined using three pO2 (oxygen partial pressure) thresholds, 5 mmHg, 7.5 mmHg and 10 mmHg, using [18F]EF5 PET/CT images for a HNC patient. FLUKA Monte Carlo simulations were then performed to calculate the oxygen enhancement ratio (OER) and relative biological effectiveness (RBE) weighted dose. Three additional treatment plans were made, one for each pO2 threshold, before OER adapting the dose objectives for the hypoxic subvolumes using Eclipse treatment planning system. Results: the method successfully defined and increased the biological dose for three pO2 threshold defined hyp...
Tumors cannot survive, progress and metastasize without recruiting new blood vessels. Vascular prope...
The dynamics of cell signalling are critical to cell fate decisions. Human Epidermal growth factor ...
A superconducting electron linear accelerator of high brilliance and low emittance (ELBE) is under o...
Background: Intra- and interfractional variations in anatomy can cause unplanned substantial alterat...
Background: Hypoxia is an important feature of most solid tumors and has shown to serve as a mediato...
MD ResApproximately half of all patients diagnosed with cancer will receive radiotherapy as a part o...
Peritoneal metastasis is relatively resistant to systemic chemotherapy and has a poor prognosis. The...
Prostate cancer (PCa) is the second most common cancer worldwide in men and one of the major causes ...
The lifetime risk of a man getting diagnosed with prostate cancer is 1 in 6. The diagnosis is made ...
p16INK4A expression is an important, independent prognostic marker in HNSCC patients. We observed a ...
Platinum chemotherapeutics like cisplatin are pivotal in the treatment of cancer. However, platinum ...
Hypertension (HTN) is a major risk factor for the development of cardiovascular disease, and it’s es...
The advancement in head and neck squamous cell carcinoma (HNSCC) therapy necessitates the acquisitio...
Multiple sclerosis (MS) is an autoimmune and neurodegenerative disease, which affects around three m...
In recent years, one important objective of cardiovascular research has been to find new markers tha...
Tumors cannot survive, progress and metastasize without recruiting new blood vessels. Vascular prope...
The dynamics of cell signalling are critical to cell fate decisions. Human Epidermal growth factor ...
A superconducting electron linear accelerator of high brilliance and low emittance (ELBE) is under o...
Background: Intra- and interfractional variations in anatomy can cause unplanned substantial alterat...
Background: Hypoxia is an important feature of most solid tumors and has shown to serve as a mediato...
MD ResApproximately half of all patients diagnosed with cancer will receive radiotherapy as a part o...
Peritoneal metastasis is relatively resistant to systemic chemotherapy and has a poor prognosis. The...
Prostate cancer (PCa) is the second most common cancer worldwide in men and one of the major causes ...
The lifetime risk of a man getting diagnosed with prostate cancer is 1 in 6. The diagnosis is made ...
p16INK4A expression is an important, independent prognostic marker in HNSCC patients. We observed a ...
Platinum chemotherapeutics like cisplatin are pivotal in the treatment of cancer. However, platinum ...
Hypertension (HTN) is a major risk factor for the development of cardiovascular disease, and it’s es...
The advancement in head and neck squamous cell carcinoma (HNSCC) therapy necessitates the acquisitio...
Multiple sclerosis (MS) is an autoimmune and neurodegenerative disease, which affects around three m...
In recent years, one important objective of cardiovascular research has been to find new markers tha...
Tumors cannot survive, progress and metastasize without recruiting new blood vessels. Vascular prope...
The dynamics of cell signalling are critical to cell fate decisions. Human Epidermal growth factor ...
A superconducting electron linear accelerator of high brilliance and low emittance (ELBE) is under o...